MIROCALS consortium is formed by 12 organisations in the EU to conduct a phase II Proof of Concept / Proof of Mechanism Clinical Trial aiming to test the interleukin-2 (IL-2) as treatment for amyotrophic lateral sclerosis (ALS).
The science of the project is coordinated by Dr Gilbert Bensimon of the University Hospital of Nimes (France) which is the trial sponsor, and Professor P. Nigel Leigh of the Brighton and Sussex Medical School (UK).
Around them, the MIROCALS consortium brings together a strong partnership of: leading scientists and clinicians from six European laboratories in France, Italy, Sweden and UK; two clinical research organisations for professional biobanking and trial regulatory-compliant monitoring; the MND Association one of the most active patients’ associations in the field of neurodegeneration worldwide and an EU project management company.
MIROCALS is a 4-year collaborative research project started in September 2015 and supported by the European Union’s Horizon 2020 research and innovation Programme.
Gilbert is a biotechnologist specializing in the human microbiome, whose research has contributed to the discovery of the impact of bacterial flora on overall health. After years of working in advanced laboratories in Europe, he returned to his roots to educate the community about the remarkable benefits of our body’s harmony with microorganisms through publications and lectures. His approach to health combines science with the practice of everyday life.